Moomoo AI 已提取核心訊息
On January 10, 2024, BML Investment Partners, L.P. filed a Schedule 13G with the SEC, indicating a significant ownership stake in Reneo Pharmaceuticals, Inc. The filing revealed that BML Investment Partners, along with Braden M Leonard, collectively hold 1,694,229 shares of Reneo Pharmaceuticals' common stock, which represents 5.1% of the company's class of securities. Braden M Leonard, identified as the Managing Member, has sole voting and dispositive power over 330,000 shares and shared power over an additional 1,364,229 shares. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, and the information provided is not deemed to be 'filed' for liability purposes under Section 18 of the Act but is subject to all other provisions of the Act. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Reneo Pharmaceuticals.
On January 10, 2024, BML Investment Partners, L.P. filed a Schedule 13G with the SEC, indicating a significant ownership stake in Reneo Pharmaceuticals, Inc. The filing revealed that BML Investment Partners, along with Braden M Leonard, collectively hold 1,694,229 shares of Reneo Pharmaceuticals' common stock, which represents 5.1% of the company's class of securities. Braden M Leonard, identified as the Managing Member, has sole voting and dispositive power over 330,000 shares and shared power over an additional 1,364,229 shares. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, and the information provided is not deemed to be 'filed' for liability purposes under Section 18 of the Act but is subject to all other provisions of the Act. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Reneo Pharmaceuticals.
2024年1月10日，BML Investment Partners, L.P. 向美國證券交易委員會提交了附表13G，表示擁有Reneo Pharmicals, Investment Investment Investment Partners的1,694,229股Renoard普通股，佔該公司證券類別的5.1％。被確認爲管理成員的佈雷登·倫納德對33萬股股票擁有唯一的投票權和處置權，對另外1,364,229股股票擁有共同的控制權。該申報是根據1934年《證券交易法》第13d-1（b）條提交的，根據該法第18條，所提供的信息不被視爲 “已提交”，但受該法所有其他條款的約束。文件顯示，這些股份是在正常業務過程中收購的，不是爲了改變或影響Reneo Pharmicals的控制權。
2024年1月10日，BML Investment Partners, L.P. 向美國證券交易委員會提交了附表13G，表示擁有Reneo Pharmicals, Investment Investment Investment Partners的1,694,229股Renoard普通股，佔該公司證券類別的5.1％。被確認爲管理成員的佈雷登·倫納德對33萬股股票擁有唯一的投票權和處置權，對另外1,364,229股股票擁有共同的控制權。該申報是根據1934年《證券交易法》第13d-1（b）條提交的，根據該法第18條，所提供的信息不被視爲 “已提交”，但受該法所有其他條款的約束。文件顯示，這些股份是在正常業務過程中收購的，不是爲了改變或影響Reneo Pharmicals的控制權。
有用
沒用